22,20 €
Deine Einschätzung
Agios Pharmaceuticals Inc. Aktie
Was spricht für und gegen Agios Pharmaceuticals Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Agios Pharmaceuticals Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -4,35 % | -25,50 % | -8,26 % | -9,76 % | -4,31 % | 5,71 % | -51,41 % |
| Ligand Pharmaceuticals | 0,52 % | 3,16 % | 13,95 % | 109,63 % | 18,07 % | 182,01 % | 62,05 % |
| United Therapeutics | -0,39 % | -0,51 % | 9,27 % | 89,27 % | 14,72 % | 133,32 % | 180,11 % |
| Ionis Pharmaceuticals Inc. | -1,25 % | -2,58 % | 4,04 % | 146,87 % | -6,68 % | 92,36 % | 79,61 % |
Kommentare
News
Here's Why Agios Pharmaceuticals Crashed 23% Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) slumped by 23% as of 11 a.m. today. As is often the case with small-cap healthcare stocks, the move isn't so much dictated by what the company is doing
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting.
That's
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals (NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly



